Medicare Rx Benefit Regs Will Be Revised Constantly, CMS Says
Executive Summary
The regulations governing the operation of the Medicare drug benefit are likely to remain in a relatively high state of flux even after implementation begins, the Centers for Medicare & Medicaid Services suggests
You may also be interested in...
Rx Industry Must Change “Mission” To Prepare For Medicare – Scully
The Medicare prescription drug benefit that begins in 2006 will fundamentally change the mission of pharmaceutical companies, former Centers for Medicare & Medicaid Services Administrator Tom Scully told the Washington Research Group's annual symposium in Washington, D.C. Nov. 5
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials